However, it’s not roses all the way, as the report has red-flagged some areas as problematic, calling for more reforms. The GIPC has pinpointed some issues which, though compatible with the global treaty on Trade-Related Intellectual Property Rights (TRIPs), seem ill-suited to innovation-based businesses looking for perpetuating their patents. The most prominent among these are the provision in the patent law for “compulsory licensing” to allow commercial production of a patented product in public or national interest and an unambiguous definition of patentability that denies extension (read ever-greening) of a patent on trivial grounds. The other purportedly objectionable aspects include barriers to licensing and technology transfer, limited framework for safeguarding bio-pharmaceutical IPRs and lengthy procedure for pre-grant opposition to patents.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)